Impact BioMedical, Inc. (IBO) Short-Term Debt to Equity

Impact BioMedical Inc (IBO) is developing diversified biomedical projects. This price chart on the GURU.Markets platform illustrates investor distrust toward opaque management and a complex ownership structure, where the metric stands at 0.00. The business relies on the synergy of treatments for diabetes and viruses. Stable revenues guarantee the defensive qualities of the assets, which remain virtually independent of global economic shocks.

Short-Term Debt to Equity Ratio: Impact BioMedical, Inc. (IBO) for 09/17/2024 - 10/30/2026

Financial and market metric breakdowns for Impact BioMedical, Inc. (IBO)

- stock quotes and analyst forecast:
Stock Price Impact BioMedical|IBO - Analyst Consensus Forecast
- market capitalization details:
Market Value Impact BioMedical, Inc.|IBO - Value Adjusted for Debt and Cash
- balance sheet equity data:
Net Assets per Single Share Impact BioMedical|IBO - Company Net Assets|Market Capitalization to Book Value Ratio impactbiomedinc.com|IBO - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Impact BioMedical Inc|IBO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Impact BioMedical Inc|IBO - Company Cumulative Debt|Debt to Book Value Impact BioMedical, Inc.|IBO - Amount of Long-Term Liabilities|Company Short-Term Debts Impact BioMedical|Quick Ratio impactbiomedinc.com
- company profitability and valuation multiples indicators:
IBO - Company Net Income
Analysis of all company metrics:Impact BioMedical IBO

To identify the sector's fundamental leaders, the analyst evaluates the ratio of liabilities maturing within one year to equity, which determines the business's ability to service urgent debts without compromising solvency. Amid geopolitical risks and raw material supply disruptions for Impact BioMedical Inc (IBO), this calculation is critical, as the current level of short-term capital load reflects the company's financial margin of safety in the event of restricted sales markets.

Key competitors

Short-Term Debt to Capital HLN|Short-Term Debt to Capital Kenvue Health (KVUE)|Short-Term Debt to Equity Verona Pharma plc VRNA|Ratio of Short-Term Indebtedness to Capital MENS|LGND - Short-Term Debt to Equity|Amneal Pharmaceuticals, Inc. (AMRX) - Short-Term Debt to Equity Ratio|PRGO: Short-Term Debt to Capital|Alvotech Biopharmaceuticals (ALVO) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio LQDA|GLPG: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity ANI Pharmaceuticals, Inc. (ANIP)|MNKD - Current Liabilities to Capital|Amphastar - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio PCRX (Pacira Corp)|ARS Pharmaceuticals - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital TBPH (theravance.com)|AQST: Short-Term Debt to Capital|Current Liabilities to Capital scPharmaceuticals (SCPH)|Short-Term Debt to Equity Tectonic Therapeutic Inc.|TNXP: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital SXTC|Short-Term Debt to Capital Coefficient eupraxiapharma.com|Short-Term Debt to Equity BioHarvest Sciences Inc. BHST|EXOZ - Short-Term Debt to Equity Ratio|ORMP - Short-Term Debt to Equity|Current Liabilities to Equity ENTX|HYFT: Short-Term Debt to Capital|abvcpharma.com (ABVC) - Short-Term Debt to Capital|CPIX (Cumberland Pharmaceuticals Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Quantum BioPharma Ltd. (QNTM)|Short-Term Debt to Equity Ratio FGEN (FibroGen Corp)|Short-Term Loans to Capital Ratio TELO|Rani Therapeutics Holdings, Inc. - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SNYR|Rallybio Corp. - Short-Term Debt to Capital|LEXX: Short-Term Debt to Equity|PULM: Short-Term Debt to Capital|PTHL - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Aptorum Group Ltd|Current Liabilities to Capital lyratherapeutics.com LYRA|Short-Term Debt to Equity TNF Pharmaceuticals (TNFA)|Short-Term Debt to Equity Ratio cbdmd.com YCBD|Short-Term Debt to Capital PRFX (PainReform Limited)|Altamira Therapeutics Ltd (CYTO) - Current Liabilities to Capital|Lipella Pharmaceuticals - Short-Term Debt to Capital|OPTN (optinose.com) - Short-Term Debt to Capital Ratio|PIRS: Short-Term Debt to Capital|PROC - Short-Term Debt to Capital Coefficient|PTPI (Petros) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Qilian International Corp (QLI)|Short-Term Debt to Capital SLRN|Short-Term Debt to Capital tffpharma.com (TFFP)